Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). The Company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis, and Friedreich’s ataxia.

Revenue(FY, 2016)

$14.2 M

Market capitalization(2018-04-20)

($496.6 M)

Patent Applications (FY, 2016)

Type

Public

Cambridge, US

Founded

2014

Size (employees)

77 (est)

Website

voyagertherapeutics.com

Voyager Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Report incorrect company information

Key People/Management at Voyager Therapeutics

Steven Paul

President and CEO

Matt Ottmer

COO

Jane Henderson

SVP & CFO

Bernard Ravina

Chief Medical Officer

Dinah Sah

Chief Scientific Officer

Luis Maranga

Chief Technical Operations Officer

Report incorrect company information

Voyager Therapeutics Office Locations

Voyager Therapeutics has an office in Cambridge

Cambridge, US (HQ)

75 Sidney St

Show all (1)

Report incorrect company information

Voyager Therapeutics Financials and Metrics

Voyager Therapeutics Financials

Voyager Therapeutics's revenue was reported to be $14.22 m in FY, 2016 which is a 18% decrease from the previous period.

Summary

USD
Net income (Q1, 2017)	(16.6 m)
Market capitalization (20-Apr-2018)	(496.6 m)

Source: SEC Filings

Income Statement

Annual

USD	FY, 2015	FY, 2016
Revenue	17.3 m	14.2 m
Revenue growth, %		(18%)
EBITDA	(20.5 m)	(41.3 m)
EBITDA margin, %	(118%)	(290%)

Quarterly

USD	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	(22.4 m)	(7.2 m)	(16.5 m)	(25.5 m)	(16.6 m)

show all

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2015	FY, 2016
Accounts Receivable		826 m
Current Assets	195.9 m	178.8 m
PP&E	3.2 m	7.9 m
Total Assets	229.5 m	189.6 m

Quarterly

USD	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	66.5 m	33.9 m	67 m
Current Assets	108.6 m	205.7 m	205.5 m	193 m	161.1 m	144.7 m
PP&E	3.3 m	3.6 m	3.6 m	4.3 m	10.1 m	10.7 m
Total Assets	166.4 m	220 m	209.8 m	202 m	175.1 m	158.4 m

show all

Cash Flow

Annual

USD	FY, 2015	FY, 2016
Net Income	(3.8 m)	(40.2 m)
Depreciation and Amortization	600 k	612 k
Inventories	(234 k)	(847 k)
Accounts Payable	950 k	(62 k)

Quarterly

USD	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Net Income	(22.4 m)	(7.2 m)	(16.5 m)	(25.5 m)	(16.6 m)	(35.5 m)
Depreciation and Amortization	436 k	136 k	288 k	448 k	317 k	726 k
Accounts Payable	(1 m)	1.1 m	(158 k)	175 k	280 k	(243 k)
Cash From Operating Activities	50.9 m	(9.5 m)	(19.2 m)	(29.4 m)	(14.3 m)	(30.6 m)